JP2009543874A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009543874A5 JP2009543874A5 JP2009520840A JP2009520840A JP2009543874A5 JP 2009543874 A5 JP2009543874 A5 JP 2009543874A5 JP 2009520840 A JP2009520840 A JP 2009520840A JP 2009520840 A JP2009520840 A JP 2009520840A JP 2009543874 A5 JP2009543874 A5 JP 2009543874A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- leukemia
- subject
- formula
- pkc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000032839 leukemia Diseases 0.000 claims description 31
- 239000000203 mixture Substances 0.000 claims description 30
- 150000001875 compounds Chemical class 0.000 claims description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 208000035475 disorder Diseases 0.000 claims description 15
- 125000003118 aryl group Chemical group 0.000 claims description 14
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 11
- 101001064870 Homo sapiens Lon protease homolog, mitochondrial Proteins 0.000 claims description 10
- 101000595531 Homo sapiens Serine/threonine-protein kinase pim-1 Proteins 0.000 claims description 10
- 102100036077 Serine/threonine-protein kinase pim-1 Human genes 0.000 claims description 10
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 8
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 8
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 8
- 230000030833 cell death Effects 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 8
- 239000000651 prodrug Substances 0.000 claims description 8
- 229940002612 prodrug Drugs 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 108090000315 Protein Kinase C Proteins 0.000 claims description 6
- 102000003923 Protein Kinase C Human genes 0.000 claims description 6
- 239000012453 solvate Substances 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 4
- 101001059984 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 4 Proteins 0.000 claims description 4
- 101001051767 Homo sapiens Protein kinase C beta type Proteins 0.000 claims description 4
- 101000945090 Homo sapiens Ribosomal protein S6 kinase alpha-3 Proteins 0.000 claims description 4
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 claims description 4
- 102100028194 Mitogen-activated protein kinase kinase kinase kinase 4 Human genes 0.000 claims description 4
- 108091000080 Phosphotransferase Proteins 0.000 claims description 4
- 108010024526 Protein Kinase C beta Proteins 0.000 claims description 4
- 102000015766 Protein Kinase C beta Human genes 0.000 claims description 4
- 108010015499 Protein Kinase C-theta Proteins 0.000 claims description 4
- 102000001892 Protein Kinase C-theta Human genes 0.000 claims description 4
- 102100024923 Protein kinase C beta type Human genes 0.000 claims description 4
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 claims description 4
- 102100033643 Ribosomal protein S6 kinase alpha-3 Human genes 0.000 claims description 4
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 claims description 4
- JDSJDASOXWCHPN-UHFFFAOYSA-N TDZD-8 Chemical compound O=C1N(C)SC(=O)N1CC1=CC=CC=C1 JDSJDASOXWCHPN-UHFFFAOYSA-N 0.000 claims description 4
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 125000001188 haloalkyl group Chemical group 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- 102000020233 phosphotransferase Human genes 0.000 claims description 4
- 210000000130 stem cell Anatomy 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 208000037516 chromosome inversion disease Diseases 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- -1 or polymorph thereof Substances 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 102100032311 Aurora kinase A Human genes 0.000 claims description 2
- 208000019838 Blood disease Diseases 0.000 claims description 2
- 101100457345 Danio rerio mapk14a gene Proteins 0.000 claims description 2
- 101100457347 Danio rerio mapk14b gene Proteins 0.000 claims description 2
- 101100181139 Drosophila melanogaster Pkcdelta gene Proteins 0.000 claims description 2
- 102100023114 Dual specificity tyrosine-phosphorylation-regulated kinase 3 Human genes 0.000 claims description 2
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 claims description 2
- 102100038104 Glycogen synthase kinase-3 beta Human genes 0.000 claims description 2
- 206010066476 Haematological malignancy Diseases 0.000 claims description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 2
- 101000798300 Homo sapiens Aurora kinase A Proteins 0.000 claims description 2
- 101001049991 Homo sapiens Dual specificity tyrosine-phosphorylation-regulated kinase 3 Proteins 0.000 claims description 2
- 101000731078 Homo sapiens Phosphorylase b kinase gamma catalytic chain, liver/testis isoform Proteins 0.000 claims description 2
- 101001026854 Homo sapiens Protein kinase C delta type Proteins 0.000 claims description 2
- 101001026852 Homo sapiens Protein kinase C epsilon type Proteins 0.000 claims description 2
- 101000971400 Homo sapiens Protein kinase C eta type Proteins 0.000 claims description 2
- 101000971404 Homo sapiens Protein kinase C iota type Proteins 0.000 claims description 2
- 101000971468 Homo sapiens Protein kinase C zeta type Proteins 0.000 claims description 2
- 101000779418 Homo sapiens RAC-alpha serine/threonine-protein kinase Proteins 0.000 claims description 2
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims description 2
- 101000669917 Homo sapiens Rho-associated protein kinase 1 Proteins 0.000 claims description 2
- 101001026885 Homo sapiens Serine/threonine-protein kinase D3 Proteins 0.000 claims description 2
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 102100034069 MAP kinase-activated protein kinase 2 Human genes 0.000 claims description 2
- 108010041955 MAP-kinase-activated kinase 2 Proteins 0.000 claims description 2
- 108700012928 MAPK14 Proteins 0.000 claims description 2
- 101150003941 Mapk14 gene Proteins 0.000 claims description 2
- 102000054819 Mitogen-activated protein kinase 14 Human genes 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 102100032391 Phosphorylase b kinase gamma catalytic chain, liver/testis isoform Human genes 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 108010078137 Protein Kinase C-epsilon Proteins 0.000 claims description 2
- 102000014458 Protein Kinase C-epsilon Human genes 0.000 claims description 2
- 102100024924 Protein kinase C alpha type Human genes 0.000 claims description 2
- 101710109947 Protein kinase C alpha type Proteins 0.000 claims description 2
- 102100037340 Protein kinase C delta type Human genes 0.000 claims description 2
- 102100037339 Protein kinase C epsilon type Human genes 0.000 claims description 2
- 102100021556 Protein kinase C eta type Human genes 0.000 claims description 2
- 102100021557 Protein kinase C iota type Human genes 0.000 claims description 2
- 102100021538 Protein kinase C zeta type Human genes 0.000 claims description 2
- 101710113459 RAC-alpha serine/threonine-protein kinase Proteins 0.000 claims description 2
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims description 2
- 102100039313 Rho-associated protein kinase 1 Human genes 0.000 claims description 2
- 102100037311 Serine/threonine-protein kinase D3 Human genes 0.000 claims description 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims description 2
- 230000009702 cancer cell proliferation Effects 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 210000000170 cell membrane Anatomy 0.000 claims description 2
- 230000004663 cell proliferation Effects 0.000 claims description 2
- 201000005787 hematologic cancer Diseases 0.000 claims description 2
- 208000014951 hematologic disease Diseases 0.000 claims description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 2
- 208000018706 hematopoietic system disease Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 230000036542 oxidative stress Effects 0.000 claims description 2
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims description 2
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 claims description 2
- 208000030151 polycystic kidney disease 3 with or without polycystic liver disease Diseases 0.000 claims description 2
- 230000002062 proliferating effect Effects 0.000 claims description 2
- 108010027883 protein kinase C eta Proteins 0.000 claims description 2
- 108010008359 protein kinase C lambda Proteins 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 20
- 206010000830 Acute leukaemia Diseases 0.000 description 2
- 208000036676 acute undifferentiated leukemia Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83189306P | 2006-07-18 | 2006-07-18 | |
| PCT/US2007/016391 WO2008011113A2 (en) | 2006-07-18 | 2007-07-18 | Thiadiazolidinone derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009543874A JP2009543874A (ja) | 2009-12-10 |
| JP2009543874A5 true JP2009543874A5 (enExample) | 2011-09-01 |
Family
ID=38957376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009520840A Pending JP2009543874A (ja) | 2006-07-18 | 2007-07-18 | チアゾリジノン誘導体 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US9180118B2 (enExample) |
| EP (1) | EP2043633B1 (enExample) |
| JP (1) | JP2009543874A (enExample) |
| AU (1) | AU2007275686B2 (enExample) |
| CA (1) | CA2658263A1 (enExample) |
| NZ (1) | NZ574619A (enExample) |
| WO (1) | WO2008011113A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2043633B1 (en) * | 2006-07-18 | 2016-07-06 | University of Rochester | Thiadiazolidinone derivatives for treating cancer |
| WO2009058394A1 (en) * | 2007-11-01 | 2009-05-07 | Celgene Corporation | Cytidine analogs for treatment of myelodysplastic syndromes |
| US20090117090A1 (en) * | 2007-11-01 | 2009-05-07 | Ottawa Heart Institute Research Corporation | Inhibition of glycogen synthase kinase 3 beta in arterial repair and stent re-endothelialization |
| WO2011151359A1 (en) * | 2010-06-02 | 2011-12-08 | Noscira, S.A. | Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative |
| JP6998657B2 (ja) | 2013-09-18 | 2022-02-04 | エピアクシス セラピューティクス プロプライエタリー リミテッド | 幹細胞調節ｉｉ |
| AU2015274334B2 (en) * | 2014-06-12 | 2020-12-17 | Cedars-Sinai Medical Center | Compositions and methods for treating cancers |
| JP6534098B2 (ja) * | 2014-09-12 | 2019-06-26 | 国立大学法人 鹿児島大学 | 成人ｔ細胞白血病治療薬 |
| KR20170129769A (ko) | 2015-03-17 | 2017-11-27 | 리제너론 파아마슈티컬스, 인크. | 아미노산 아실화 시약 및 이의 사용 방법 |
| CN109715166A (zh) * | 2016-07-14 | 2019-05-03 | 深圳明赛瑞霖药业有限公司 | 癌症的治疗 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1507799A (en) | 1997-12-16 | 1999-07-05 | Sankyo Company Limited | Leukemia remedy |
| JPH11335298A (ja) * | 1997-12-16 | 1999-12-07 | Sankyo Co Ltd | 白血病治療剤 |
| AU2001248365A1 (en) | 2000-03-23 | 2001-10-03 | Mitsubishi Pharma Corporation | 2-(arylalkylamino)pyrimidone derivatives and 2-(heteroarylalkylamino)pyrimidone derivatives |
| CZ296087B6 (cs) * | 2000-05-11 | 2006-01-11 | Consejo Superior Investigaciones Cientificas | Farmaceutický prostredek pro lécbu nemoci, na nízse podílí heterocyklické inhibitory glykogensyntázakinázy GSK-3 |
| ES2166328B1 (es) * | 2000-05-11 | 2003-09-16 | Consejo Superior Investigacion | Inhibidores heterociclicos del enzima gsk 3 utiles en el tratamiento de procesos neurodegenerativos e hiperproliferativos |
| EP1586318A1 (en) * | 2004-04-05 | 2005-10-19 | Neuropharma S.A.U. | Thiadiazolidinones as GSK-3 inhibitors |
| FI20041129A0 (fi) * | 2004-08-30 | 2004-08-30 | Ctt Cancer Targeting Tech Oy | Tioksotiatsolidinoniyhdisteitä lääkkeinä käytettäviksi |
| WO2006045581A1 (en) * | 2004-10-21 | 2006-05-04 | Neuropharma, S.A. | The use of 1, 2, 4-thiadiazolidine-3, 5-diones as ppar activators |
| US20060204980A1 (en) * | 2004-12-28 | 2006-09-14 | Altieri Dario C | Colorectal cancer therapies |
| US20070196514A1 (en) * | 2006-02-21 | 2007-08-23 | Benyi Li | Prostate cancer treatment with glycogen synthase kinase-3beta inhibitors |
| EP2043633B1 (en) * | 2006-07-18 | 2016-07-06 | University of Rochester | Thiadiazolidinone derivatives for treating cancer |
-
2007
- 2007-07-18 EP EP07810619.2A patent/EP2043633B1/en not_active Not-in-force
- 2007-07-18 US US12/374,002 patent/US9180118B2/en not_active Expired - Fee Related
- 2007-07-18 NZ NZ574619A patent/NZ574619A/en not_active IP Right Cessation
- 2007-07-18 AU AU2007275686A patent/AU2007275686B2/en not_active Ceased
- 2007-07-18 JP JP2009520840A patent/JP2009543874A/ja active Pending
- 2007-07-18 WO PCT/US2007/016391 patent/WO2008011113A2/en not_active Ceased
- 2007-07-18 CA CA002658263A patent/CA2658263A1/en not_active Abandoned
-
2015
- 2015-10-08 US US14/878,330 patent/US20160058741A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009543874A5 (enExample) | ||
| JP7402549B2 (ja) | Ｃｘｃｒ４阻害剤およびその使用 | |
| KR102444482B1 (ko) | 단백질 인산화효소 억제제로서의 1h-이미다조[4,5-h]퀴나졸린 화합물 | |
| US10913727B2 (en) | Modulators of the integrated stress pathway | |
| JP5637852B2 (ja) | ６、７又は８置換キナゾリノン誘導体並びにそれらを含有する組成物及びそれらを使用する方法 | |
| EP3704091B1 (en) | INTEGRATED STRESS RESPONSE PATH MODULATORS | |
| US20240307382A1 (en) | Modulators of the integrated stress pathway | |
| JP6133383B2 (ja) | ５−置換キナゾリノン誘導体、それを含む組成物、及びその使用方法 | |
| EP3173100B1 (en) | Therapeutic combination comprising a cdks inhibitor and oxaliplatin | |
| TW202019900A (zh) | Ptpn11抑制劑 | |
| JP6500037B2 (ja) | 二環式ピラゾロン化合物および使用方法 | |
| RS57177B1 (sr) | Derivati benzamida za inhibiranje aktivnosti abl1, abl2 i bcr-abl1 | |
| JP2021502388A (ja) | Ａｓｈ１ｌ阻害剤及びそれを用いた治療方法 | |
| EP2861576A1 (en) | Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 | |
| HUE026041T2 (en) | Pyrrolo-triazinone derivatives as P13K inhibitors | |
| JP2017508787A (ja) | 医薬化合物 | |
| BR112015006019B1 (pt) | composto e uso de um composto | |
| JP2007529421A5 (enExample) | ||
| TWI759316B (zh) | Bcl-2抑制劑及mcl1抑制劑之組合、其用途及醫藥組合物 | |
| EP2501385B1 (en) | Therapeutic combination comprising a cdc7 inhibitor and an antineoplastic agent | |
| WO2020068600A1 (en) | Ubiquitin-specific-processing protease 7 (usp7) modulators and uses thereof | |
| EP3283482A1 (en) | Plk4 inhibitors | |
| JP2025519119A (ja) | Ｍｅｋ阻害剤及びその使用 | |
| BR112019017962A2 (pt) | método para inibição de crescimento, de migração, de proliferação e/ou de metástase de uma célula pré-cancerosa, cancerosa ou neoplásica ou de inibição de um patógeno, composição probiótica tópica, bandagem ou curativo, método de tratamento de dano na pele devido à radiação uv, e, composição farmacêutica | |
| JP2009537606A5 (enExample) |